about
Splenectomy for people with thalassaemia major and intermediaSplenectomy for people with thalassaemia major or intermediaβ-thalassemia intermedia: a clinical perspectivePregnancy in women with thalassemia: challenges and solutionsMoyamoya syndrome in a splenectomized patient with beta-thalassemia intermedia2-Butoxyethanol female-rat model of hemolysis and disseminated thrombosis: X-ray characterization of osteonecrosis and growth-plate suppression.Platelet aggregation and activation in thalassemia major patients in Indonesia.Thalassemia major-- on the verge of bleeding or thrombosis?Short- and long-term risks of splenectomy for benign haematological disorders: should we revisit the indications?Subclinical haemorrhagic tendency exists in patients with β-thalassaemia major in early childhoodPulmonary hypertension in patients with hematological disorders following splenectomy.Future alternative therapies for β-thalassemia.Placenta growth factor (PlGF), a novel inducer of plasminogen activator inhibitor-1 (PAI-1) in sickle cell disease (SCD).Hydroxycarbamide-induced changes in E/beta thalassemia red blood cellsNovel approach to reactive oxygen species in nontransfusion-dependent thalassemiaBenefits of chronic blood transfusion in hemoglobin E/β thalassemia with pulmonary arterial hypertensionVascular endothelial dysfunction in β-thalassemia occurs despite increased eNOS expression and preserved vascular smooth muscle cell reactivity to NOHemolysis-associated pulmonary hypertension in thalassemia.Red blood cells, platelets and polymorphonuclear neutrophils of patients with sickle cell disease exhibit oxidative stress that can be ameliorated by antioxidants.[Genetics of ischemic stroke].Sickle cell disease and venous thromboembolism.Inherited trombophilic states and pulmonary embolism.Erythrocyte-derived microparticles supporting activated protein C-mediated regulation of blood coagulationβ-thalassemia: a model for elucidating the dynamic regulation of ineffective erythropoiesis and iron metabolism.Pleiotropic effects of intravascular haemolysis on vascular homeostasis.Nitric oxide and arginine dysregulation: a novel pathway to pulmonary hypertension in hemolytic disordersGenetic insights into the clinical diversity of beta thalassaemia.Hematopoietic stem cell mobilization for gene therapy of adult patients with severe β-thalassemia: results of clinical trials using G-CSF or plerixafor in splenectomized and nonsplenectomized subjectsSplenectomy: a strong risk factor for pulmonary hypertension in patients with thalassaemia.Genetic diminution of circulating prothrombin ameliorates multiorgan pathologies in sickle cell disease miceHemoglobin interaction with GP1bα induces platelet activation and apoptosis: a novel mechanism associated with intravascular hemolysis.Central venous line-related thrombosis in children.Sickle cell-β thalassemia with concomitant hemophilia A: a rare presentation.Modern treatment of thalassaemia intermedia.Non-transfusion-dependent thalassemias.Beta-thalassaemia and sickle cell anaemia as paradigms of hypercoagulability.Effects of chelation therapy on cardiac function improvement in thalassemia patients: literature review and the Taiwanese experience.Congestive heart failure and treatment in thalassemia major.Transcranial Doppler Ultrasonography in Beta-thalassemia Major Patients Without and With ThrombocytosisSildenafil therapy in thalassemia patients with Doppler-defined risk of pulmonary hypertension
P2860
Q24202998-E26358B9-9DEC-4524-8490-35705412DAADQ26471468-A078C20D-CCA8-46EC-B1CE-BF29D3579DE3Q26828512-B7FFEB74-F230-4D2A-94A0-80A6E26B9AACQ28080216-EE7C11D3-68A2-4F55-8AFA-B063F14D5D67Q28195861-5A7E0C79-EA46-4B98-93D3-83C1636FD205Q30990151-B64CE979-E7F6-4E0B-A448-83BDFCCB2324Q33312413-0EC17CF2-DEC9-46A9-ACD8-A6167917AD49Q33370469-9F43F438-B7DE-480C-A2E1-3178D27ACB39Q33401130-0D4C0483-30CB-46EB-824B-5A5CA1F670EFQ33402872-66A55846-595E-46AC-B9FF-0D3FDE008079Q33404045-56AAB864-975C-4CF0-8F6D-2839D0B8E2DCQ33659678-87161885-465B-421C-9E0B-D7AEB44580CAQ33883207-464A51C8-DFFC-44AC-9C2D-7215D140D367Q33895455-0670039B-80F0-4FCB-831C-51D6E3DA02F4Q33993973-DC8B9F69-72B4-43BB-8537-C34951629C9CQ34094137-BC7CF38F-E14C-4459-8CD6-CE7861402E04Q34313817-BE942993-331B-47DB-A0DF-1C4A97C0FE9FQ34474615-2E5B282B-32B7-4961-8EC6-78A944C1CC02Q34478678-5799C097-2D6C-480C-8280-D81F2B2B2D44Q34555157-B9E7587C-D210-428F-997B-6AE3458ED4E9Q35039996-7B092125-CBBB-4029-9FEA-CFD7B30DE506Q35084785-1DB518D9-20C3-4CA8-A31F-0E138231738FQ35227861-ED7154F1-AE93-4A8F-98B4-D7B8ECE440BEQ35485724-E6DC3326-1ED4-4CBB-9603-681AAA61FCEFQ35535204-C22CE6BA-E534-4EC4-800A-5515A1C02583Q35590733-4F796049-B400-4392-A1B0-6BB0B7512BA2Q35626388-51215205-89C1-4522-AA69-900DA444696DQ35665207-AA2105CF-8CAD-4AEC-BBB5-BFCDBE71717EQ35772015-7AED9916-36D3-4EC4-BB19-7E9DB7E2870BQ36143261-571A8797-2431-4CF3-A585-02E38E0A5F49Q36337571-70BCB157-725D-45C2-8421-8E64D5CCA0FEQ36426649-B9F8B80C-5E31-4798-A83C-C75EDE4CBCE8Q36441448-BDA461DE-BEFC-4CFE-82D2-D43A33C49059Q36848269-A434410C-584C-4AA6-B037-E2770E41D403Q36892558-AD4F1EDB-ED8C-4C87-9FC8-F09D8442D571Q36940035-55046168-7027-42DB-8E9D-DD8947FAC190Q37084714-2E049A9B-063D-484C-91F4-EF184AB6B372Q37084718-B1147109-4D7F-4DBC-B196-2D0ADAFAF895Q37100695-D47B81C5-E776-4987-84CC-D0251EE50868Q37144856-F0E38AFA-C914-4006-8637-43B3C9CE8DB6
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
The hypercoagulable state in thalassemia.
@ast
The hypercoagulable state in thalassemia.
@en
The hypercoagulable state in thalassemia.
@nl
type
label
The hypercoagulable state in thalassemia.
@ast
The hypercoagulable state in thalassemia.
@en
The hypercoagulable state in thalassemia.
@nl
prefLabel
The hypercoagulable state in thalassemia.
@ast
The hypercoagulable state in thalassemia.
@en
The hypercoagulable state in thalassemia.
@nl
P356
P1433
P1476
The hypercoagulable state in thalassemia.
@en
P2093
Amiram Eldor
Eliezer A Rachmilewitz
P356
10.1182/BLOOD.V99.1.36
P407
P577
2002-01-01T00:00:00Z